TNF receptor associated periodic syndrome: Difference between revisions
No edit summary |
No edit summary |
||
Line 23: | Line 23: | ||
In [year], [diagnostic test/therapy] was developed by [scientist] to treat/diagnose [disease name]. | In [year], [diagnostic test/therapy] was developed by [scientist] to treat/diagnose [disease name]. | ||
==Classification== | ==Classification== | ||
There is no established system for the classification of | There is no established system for the classification of TNF receptor associated periodic syndrome. | ||
==Pathophysiology== | ==Pathophysiology== | ||
TNF receptor associated periodic syndrome is an autosomal inherited | |||
==Differentiating ((Page name)) from Other Diseases== | ==Differentiating ((Page name)) from Other Diseases== | ||
[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3]. | [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3]. |
Revision as of 14:40, 18 June 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: TRAPS; familial Hibernian fever
Overview
TNF receptor associated periodic syndrome (also known as TRAPS or familial Hibernian fever) is a periodic fever syndrome associated with mutations in a receptor for the molecule tumor necrosis factor (TNF) that is inheritable in an autosomal dominant manner. Individuals with TRAPS have episodic symptoms such as recurrent high fevers, rash, abdominal pain, joint/muscle aches and puffy eyes. TRAPS was first described in 1982 in a boy of Scottish-Irish origin. At that time, it was named familial Hibernian fever.
The main source of TNF is cells in the immune system called macrophages which produce it in response to infection and other stimuli. TNF helps activate other immune cells and plays a major role in the initiation of inflammation. Individuals with TRAPS have a mutation in the tumor necrosis factor receptor-1 (TNFR1) gene. The mechanisms by which mutations in TNFR1 lead to the TRAPS phenotype are still under investigation.
Several medications have been studied for the treatment of TRAPS including etanercept, infliximab[1], tacrolimus[2] and Il-1Ra (anakinra)[3]. Studies on treatment efficacy in a larger group of patients affected with TRAPS are however lacking to date.
Historical Perspective
[Disease name] was first discovered by [name of scientist], a [nationality + occupation], in [year]/during/following [event].
The association between [important risk factor/cause] and [disease name] was made in/during [year/event].
In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].
There have been several outbreaks of [disease name], including -----.
In [year], [diagnostic test/therapy] was developed by [scientist] to treat/diagnose [disease name].
Classification
There is no established system for the classification of TNF receptor associated periodic syndrome.
Pathophysiology
TNF receptor associated periodic syndrome is an autosomal inherited
Differentiating ((Page name)) from Other Diseases
[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
Epidemiology and Demographics
References
- ↑ Church LD, Churchman SM, Hawkins PN, McDermott MF. Hereditary auto-inflammatory disorders and biologics. Springer Semin Immunopathol. 2006 Jun;27(4):494-508. Epub 2006 May 4. PMID 16738958
- ↑ Ida H, Aramaki T, Arima K, Origuchi T, Kawakami A, Eguchi K. Successful treatment using tacrolimus (FK506) in a patient with TNF receptor-associated periodic syndrome (TRAPS) complicated by monocytic fasciitis. Rheumatology (Oxford). 2006 Jun 26; PMID 16801330
- ↑ Gattorno M, Pelagatti MA, Meini A, Obici L, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2008;58:1516-1520. PMID 18438813